20% Sub-Q Ig Therapy — a first-in-class product from CSL Behring

CSL Behring received approval from the FDA in March to begin marketing Hizentra, a 20% subcutaneous formulation for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra, provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

Hizentra is the first 20% subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA. This high-concentration product is stabilized with L-proline, a naturally-occurring amino acid which allows the medication to be stored at room temperature, offering patients and physicians convenience and portability. Hizentra can be safely self-administered by PI patients under a physician's care.

PI medications are typically intravenously infused and result in severe side effects and infusion site reactions. Now, PI patients have a new treatment option with the freedom to self-administer their IG therapy when and where it suits them.